关于部分首次公开发行前已发行股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：301207 证券简称：华兰疫苗 公告编号：2025-035 华兰生物疫苗股份有限公司 特别提示： 1、本次上市流通的限售股为公司部分首次公开发行前已发行股份； 2、本次解除限售股东户数共计 2 户，为华兰生物工程股份有限公司（以下简称 "华兰生物"）和科康有限公司（以下简称"香港科康"），解除限售的股份数量 共计 459,000,000 股，占公司总股本的 76.37%。 3、本次解除限售的股份上市流通日期为 2025 年 8 月 18 日（星期一）。 一、首次公开发行前已发行股份概况 经深圳证券交易所《关于华兰生物疫苗股份有限公司人民币普通股股票在创业 板上市的通知》（深证上[2022]154 号）同意，华兰生物疫苗股份有限公司（以下简 称"公司"或"华兰疫苗"）首次公开发行人民币普通股（A 股）股票 40,010,000 股， 并于 2022 年 2 月 18 日在深圳证券交易所创业板上市交易。公司首次公开发行股票 前总股本为 360,000, ...

核查意见 华泰联合证券有限责任公司 关于华兰生物疫苗股份有限公司 部分首次公开发行前已发行股份上市流通的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作为华 兰生物疫苗股份有限公司（以下简称"华兰疫苗"或"公司"）首次公开发行股票并 在创业板上市持续督导阶段的保荐人，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》及《深圳证券交易所上市公司自律监管 指引第 13 号——保荐业务》等规定，对华兰疫苗部分首次公开发行前已发行股 份上市流通事项进行了审慎核查，并出具核查意见如下： 一、首次公开发行前已发行股份概况 经深圳证券交易所《关于华兰生物疫苗股份有限公司人民币普通股股票在创 业板上市的通知》（深证上[2022]154 号）同意，公司首次公开发行人民币普通 股（A 股）股票 40,010,000 股，并于 2022 年 2 月 18 日在深圳证券交易所创业板 上市交易。公司首次公开发行股票前总股本为 360,000,000 股，首次公开发行完 成后，公司总股本为 400,010,00 ...

Group 1 - Kaizhong Precision plans to invest up to 250 million yuan to establish a subsidiary and build a production base in Thailand, focusing on overseas connector and precision component business [1] - Longbo Technology reported a 60.18% year-on-year increase in net profit for the first half of 2025, with revenue of 122 million yuan, up 18.03% [2] - Dingyang Technology achieved a net profit of 76.88 million yuan in the first half of 2025, a year-on-year increase of 31.54%, with revenue of 279 million yuan, up 24.61% [4] Group 2 - Heng Rui Pharmaceutical received approval for clinical trials of two drugs, SHR-A2102 and Adebeli monoclonal antibody injection [6] - Maolai Optical plans to use up to 100 million yuan of idle funds for entrusted wealth management to improve fund utilization efficiency [8] - Shiji Information signed a major contract with MGM Grand, providing a next-generation cloud-based hotel information management system [7] Group 3 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 4 - Aolaide expects a net profit decrease of 68.41% to 72.77% for the first half of 2025, with revenue projected between 270 million and 290 million yuan [12] - Feilong Co. used 111 million yuan of idle funds for cash management through structured deposit products [13] - Anhui Construction won two major projects with a total investment exceeding 6.6 billion yuan [15] Group 5 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 6 - China Medical's subsidiary received approval for the listing of fumaric acid volnora raw materials [20] - Huayuan Vaccine's subsidiary received approval for clinical trials of Hib vaccine [29] - Ganfeng Lithium plans to integrate lithium salt lake projects in Argentina and provide financial support of up to 130 million USD [41]

Core Viewpoint - Hualan Biological's subsidiary has received approval for a clinical trial of a new vaccine, indicating progress in its vaccine development pipeline [2] Group 1: Company Announcement - Hualan Biological announced on August 13 that its subsidiary, Hualan Biological Vaccine Co., Ltd., received a clinical trial approval notice from the National Medical Products Administration [2] - The approved clinical trial is for a "lyophilized type b Haemophilus influenzae conjugate vaccine" [2]

证券代码：301207 证券简称：华兰疫苗 公告编号：2025- 华兰生物疫苗股份有限公司 关于冻干b型流感嗜血杆菌结合疫苗获得 二、产品的相关情况 流感嗜血杆菌为革兰氏阴性杆菌，是儿童急性下呼吸道感染最主要的病原菌之 一，分为有荚膜型和无荚膜型，两者均可引发感染。无荚膜型菌株常可引发中耳炎 和鼻窦炎等疾病。主要由鼻咽部定植细菌在邻近部位传播所致；继发于血流侵袭的 感染通常由荚膜型菌株引起。有荚膜的菌株根据荚膜多糖的化学成分来进行分类， 迄今已发现 6 种血清型，其中，约 95%的侵袭性流感嗜血杆菌疾病由 b 型引起。 药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生物疫苗股份有限公司（以下简称"公司"）于近日收到国家药品监督管理 局核准签发的关于冻干b型流感嗜血杆菌结合疫苗（以下简称"Hib疫苗"）的《药物 临床试验批准通知书》。具体情况如下： 一、通知书基本情况 产品名称：冻干b型流感嗜血杆菌结合疫苗 注册分类：预防用生物制品3.3类 申请事项：境内生产药品注册临床试验 申请人：华兰生物疫苗股份有限公司 通知书编号：20 ...

华兰生物公告，控股子公司华兰疫苗申报的"冻干b型流感嗜血杆菌结合疫苗"临床试验申请获得国家药 品监督管理局批准。该疫苗用于预防由b型流感嗜血杆菌引起的侵袭性感染，包括脑膜炎、肺炎、败血 症等。疫苗公司将尽快开展相关临床试验工作。 ...

（记者 王瀚黎） 每经头条（nbdtoutiao）——美罢免劳工统计局长后，首个重要数据再遭质疑：样本缺失、数据缩水、 人员短缺，7月CPI还能信吗？ 每经AI快讯，华兰疫苗8月13日晚间发布公告称，华兰生物疫苗股份有限公司于近日收到国家药品监督 管理局核准签发的关于冻干b型流感嗜血杆菌结合疫苗的《药物临床试验批准通知书》。 ...

Core Viewpoint - Hualan Vaccine has received approval from the National Medical Products Administration for clinical trials of its Hib vaccine, which targets invasive infections caused by Haemophilus influenzae type b [1] Group 1: Company Developments - Hualan Vaccine announced on August 13 that it has obtained the clinical trial approval notice for its freeze-dried Hib vaccine [1] - The Hib vaccine is intended to prevent invasive infections such as meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis caused by Haemophilus influenzae type b [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of a lyophilized Haemophilus influenzae type b (Hib) conjugate vaccine, which is expected to induce an immune response against Hib and provide protection to recipients [1] Group 1: Vaccine Development - The Hib vaccine is composed of purified Hib polysaccharide combined with tetanus toxoid protein and is presented in a lyophilized form [1] - The company is also developing a combination vaccine based on the DTP (diphtheria, tetanus, and pertussis) components, with the Hib vaccine being one of the components [1] - Vaccine development is described as a complex and rigorous scientific activity, characterized by significant challenges and long timelines [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of its Hib vaccine, which targets Haemophilus influenzae type b, a major pathogen causing acute lower respiratory infections in children [1] Group 1: Vaccine Development - The Hib vaccine is developed using purified Hib capsular polysaccharide combined with tetanus toxoid protein, and it is expected to induce an immune response against Hib, providing protection to the vaccinated individuals [1] - The company is also developing a combination vaccine based on the DTP (Diphtheria, Tetanus, Pertussis) framework, with the Hib vaccine as one of its components [1] Group 2: Clinical Trial and Regulatory Process - The Hib vaccine, as an unapproved single vaccine, requires the accumulation of clinical data to complete its registration application for market approval [1] - Successful registration of the Hib single vaccine will support future registration applications for the combination vaccine based on the DTP framework [1]